US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enveric Biosciences

1.15

-0.0700-5.74%

Post-market: 1.230.0800+6.96%19:52 EDT

Volume:163.28K

Turnover:192.54K

Market Cap:2.84M

PE:-0.11

High:1.23

Open:1.23

Low:1.14

Close:1.22

Loading ...

Overview Company News Filings

Enveric Biosciences receives second notice of allowance from USPTO for EVM401

Enveric Biosciences Secures U.S. Patent Allowance for Innovative Non-Hallucinogenic Mescaline Derivatives in Mental Health Treatment

Enveric Biosciences announces results of EB-003 preclinical model

Enveric Biosciences Announces Positive Preclinical Results for PTSD Treatment with Lead Drug Candidate EB-003

Enveric Biosciences Reveals New Data Expanding Clinical Potential of Lead Candidate EB-003 for CNS Disorders

Enveric Biosciences to Participate in BIO International Convention

Enveric Biosciences Secures Notice of Allowance for Innovative Non-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Inc. Conducted Annual Stockholders Meeting

Enveric Biosciences Secures U.S. Patent for Novel Melatonin Receptor-Targeting Compounds, Boosting Sleep and CNS Therapeutics Potential

BRIEF-Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003

Enveric Biosciences announces results from EB-003 trial

Enveric Biosciences Announces Positive Preclinical Results for Depression Drug Candidate EB-003

Enveric Biosciences files new provisional patent application

Enveric Biosciences Announces New Provisional Patent Application for Promising Neuroplastogen Candidates Targeting Neurodegenerative Diseases

BRIEF-Enveric Biosciences Q1 Net Income USD -2.2 Million

Enveric Biosciences Q1 EPS $(1.22) Up From $(9.21) YoY

Enveric Biosciences Secures U.S. Patent for Innovative Mescaline Derivative Compounds in EVM401 Series

Press Release: Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Enveric Biosciences Q4 2024 GAAP EPS $(4.83) Misses $(0.23) Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ENVB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENVB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENVB\",,,,,undefined,":{"symbol":"ENVB","market":"US","secType":"STK","nameCN":"Enveric Biosciences","latestPrice":1.15,"timestamp":1754078400000,"preClose":1.22,"halted":0,"volume":163281,"hourTrading":{"tag":"盘后","latestPrice":1.23,"preClose":1.15,"latestTime":"19:52 EDT","volume":832,"amount":999.8361,"timestamp":1754092339097},"delay":0,"floatShares":2447454,"shares":2471656,"eps":-10.504156,"marketStatus":"Market Closed","change":-0.07,"latestTime":"08-01 16:00:00 EDT","open":1.23,"high":1.2342,"low":1.14,"amount":192544.28613239998,"amplitude":0.077213,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.504156,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754294400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.22,"preHourTrading":{"tag":"盘前","latestPrice":1.21,"preClose":1.22,"latestTime":"09:25 EDT","volume":3717,"amount":4492.7568567,"timestamp":1754054700109},"postHourTrading":{"tag":"盘后","latestPrice":1.23,"preClose":1.15,"latestTime":"19:52 EDT","volume":832,"amount":999.8361,"timestamp":1754092339097},"volumeRatio":1.9292418694023141,"impliedVol":6.7116,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENVB\",,,,,undefined,":{"symbol":"ENVB","floatShares":2447454,"roa":"-83.70%","roe":"-178.91%","lyrEps":-19.039544,"volumeRatio":1.9292418694023141,"shares":2471656,"dividePrice":0,"high":1.2342,"amplitude":0.077213,"preClose":1.22,"low":1.14,"week52Low":1.01,"pbRate":"0.73","week52High":8.949,"institutionHeld":0.0138,"latestPrice":1.15,"eps":-10.504156,"divideRate":0,"volume":163281,"delay":0,"ttmEps":-10.504156,"open":1.23,"prevYearClose":5.376,"prevWeekClose":1.31,"prevMonthClose":1.22,"prevQuarterClose":1.21,"fiveDayClose":1.31,"twentyDayClose":1.26,"sixtyDayClose":1.21},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENVB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553243595","title":"Enveric Biosciences receives second notice of allowance from USPTO for EVM401","url":"https://stock-news.laohu8.com/highlight/detail?id=2553243595","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553243595?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:55","pubTimestamp":1753275348,"startTime":"0","endTime":"0","summary":"Enveric Biosciences (ENVB) announced a second notice of allowance from the USPTO for novel compounds within its EVM401 Series, expanding its intell...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-receives-second-notice-of-allowance-from-uspto-for-evm401-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-receives-second-notice-of-allowance-from-uspto-for-evm401-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2553210940","title":"Enveric Biosciences Secures U.S. Patent Allowance for Innovative Non-Hallucinogenic Mescaline Derivatives in Mental Health Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2553210940","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553210940?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:03","pubTimestamp":1753272208,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Secures U.S. Patent Allowance for Innovative Non-Hallucinogenic Mescaline Derivatives in Mental Health Treatment. Enveric Biosciences has received a second Notice of Allowance from the United States Patent and Trademark Office for its EVM401 Series. This patent covers novel, non-hallucinogenic mescaline derivatives designed to modulate neurotransmitters relevant to neuropsychiatric disorders. The compounds are inspired by methylone but are structurally differentiated to ensure strong intellectual property protection. This advancement strengthens Enveric's position in developing neuroplastogenic small-molecule therapeutics aimed at treating mental health disorders such as PTSD. Further preclinical testing is anticipated to assess the safety and efficacy of these compounds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL6ZFs7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2551282160","title":"Enveric Biosciences announces results of EB-003 preclinical model","url":"https://stock-news.laohu8.com/highlight/detail?id=2551282160","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551282160?lang=en_us&edition=fundamental","pubTime":"2025-07-15 21:41","pubTimestamp":1752586896,"startTime":"0","endTime":"0","summary":"Enveric Biosciences (ENVB) announced results in a preclinical, exposure-based therapeutic model for post-traumatic stress disorder. In fear conditi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-announces-results-of-eb-003-preclinical-model-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-announces-results-of-eb-003-preclinical-model-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4108","ENVB","BK4077","BK4007","EB"],"gpt_icon":0},{"id":"2551670301","title":"Enveric Biosciences Announces Positive Preclinical Results for PTSD Treatment with Lead Drug Candidate EB-003","url":"https://stock-news.laohu8.com/highlight/detail?id=2551670301","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551670301?lang=en_us&edition=fundamental","pubTime":"2025-07-15 21:03","pubTimestamp":1752584609,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Inc., a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, announced positive results from a preclinical study of its lead drug candidate, EB-003. The study demonstrated that EB-003 significantly decreased context-induced freezing behavior in a well-established rodent model for post-traumatic stress disorder  when measured one hour after administration. These results suggest a positive therapeutic effect and rapid fear extinction. EB-003, a neuroplastogen, may enhance hippocampal neuroplasticity without causing hallucinations, potentially improving treatment outcomes for PTSD. Current FDA-approved treatments, such as SSRIs, only result in full remission for 20% to 30% of patients and require several weeks before benefits are observed. The study compared EB-003's effects to those of MDMA, a controlled substance that has shown clinical benefits in PTSD treatment but is not FDA-approved.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nNDL2xjFsB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXSR","BK4007","ENVB","BK4211"],"gpt_icon":0},{"id":"2545332280","title":"Enveric Biosciences Reveals New Data Expanding Clinical Potential of Lead Candidate EB-003 for CNS Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2545332280","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545332280?lang=en_us&edition=fundamental","pubTime":"2025-06-24 21:03","pubTimestamp":1750770207,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass.---- Enveric Biosciences Inc. , a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics, has announced new data regarding its lead development candidate, EB-003. The data reveals that EB-003 acts as an agonist of the serotonin receptor 5-HT1B, a validated target for drugs treating major depressive disorder and various neurological conditions such as Parkinson's disease, migraines, and cluster headaches. These results, which add to existing evidence of EB-003's receptor engagement activities, were presented by the company. The study highlighted EB-003's potential to elicit neuroplastogenic effects without adverse hallucinogenic outcomes, broadening its clinical indication potential. Enveric Biosciences plans to continue IND-enabling activities for EB-003 through 2025, as part of its strategy to explore therapeutic opportunities in psychiatric and neurological markets.Disclaimer: This news brief was created by Public Technologies  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL4kjLvV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB","EXSR","BK4211","BK4007"],"gpt_icon":0},{"id":"2543860618","title":"Enveric Biosciences to Participate in BIO International Convention","url":"https://stock-news.laohu8.com/highlight/detail?id=2543860618","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543860618?lang=en_us&edition=fundamental","pubTime":"2025-06-16 22:46","pubTimestamp":1750085177,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Inc. will participate in the 2025 BIO International Convention from June 16-19 in Boston, Massachusetts. During the event, CEO Joseph Tucker, Ph.D., will conduct one-on-one meetings with registered investors and potential partners to showcase the company's business and development strategy, recent corporate achievements, and anticipated milestones.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire  on June 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL4b7FgG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2542312476","title":"Enveric Biosciences Secures Notice of Allowance for Innovative Non-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2542312476","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542312476?lang=en_us&edition=fundamental","pubTime":"2025-06-10 21:03","pubTimestamp":1749560606,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Secures Notice of Allowance for Innovative Non-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders. Enveric Biosciences announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering a novel class of aminated tryptamine derivatives. These compounds, designed to address psychiatric and neurological disorders, are non-hallucinogenic psychedelic analogs and represent a first-in-class approach to mental health treatments. The patented molecules, developed through Enveric's proprietary discovery platform, promise improved safety and scalability, with applications for conditions like depression and anxiety without hallucinogenic side effects.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL2YCfHb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2540702635","title":"Enveric Biosciences Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540702635","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540702635?lang=en_us&edition=fundamental","pubTime":"2025-06-04 04:30","pubTimestamp":1748982657,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Inc. held its 2025 Annual Meeting of Stockholders on May 29, 2025. During the meeting, stockholders voted on several key proposals. The election of six directors was approved. The conditional approval to authorize the board of directors to amend the certificate of incorporation to effect a reverse stock split, in the range between 1:5 and 1:50, was also approved. Additionally, the ratification and appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Ana","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL4JNrsH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2540774977","title":"Enveric Biosciences Secures U.S. Patent for Novel Melatonin Receptor-Targeting Compounds, Boosting Sleep and CNS Therapeutics Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2540774977","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540774977?lang=en_us&edition=fundamental","pubTime":"2025-06-03 21:01","pubTimestamp":1748955704,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Secures U.S. Patent for Novel Melatonin Receptor-Targeting Compounds, Boosting Sleep and CNS Therapeutics Potential. Enveric Biosciences has announced the issuance of a new U.S. patent  covering a novel family of molecules with potential applications in treating sleep and central nervous system  disorders. This patent enhances the company's intellectual property portfolio and includes selective melatonin receptor-binding compounds, which could be used to target sleep disorders. Among the covered molecules are potential MT1-selective agonists, suggesting promise for innovative sleep therapeutics. The patent further supports Enveric's CNS-focused strategy, targeting high-value therapeutic markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL98WdPn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2538472196","title":"BRIEF-Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003","url":"https://stock-news.laohu8.com/highlight/detail?id=2538472196","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538472196?lang=en_us&edition=fundamental","pubTime":"2025-05-28 22:47","pubTimestamp":1748443647,"startTime":"0","endTime":"0","summary":"BRIEF-Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003May 28 (Reuters) - Enveric Biosciences Inc ENVB.O:ENVERIC BIOSCIENCES REPORTS POSITIVE PRECLINICAL RESULTS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nTUA7PT4WX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2538792264","title":"Enveric Biosciences announces results from EB-003 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2538792264","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538792264?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:10","pubTimestamp":1748437843,"startTime":"0","endTime":"0","summary":"Enveric Biosciences (ENVB) announced preclinical results for its lead neuroplastogen drug candidate, EB-003, in the Open Space Forced Swim Test, a ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-announces-results-from-eb-003-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-announces-results-from-eb-003-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4077","BK4007","EB","BK4108","ENVB"],"gpt_icon":0},{"id":"2538479569","title":"Enveric Biosciences Announces Positive Preclinical Results for Depression Drug Candidate EB-003","url":"https://stock-news.laohu8.com/highlight/detail?id=2538479569","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538479569?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:03","pubTimestamp":1748437398,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Inc. has announced positive preclinical results for its lead drug candidate, EB-003, aimed at treating severe chronic depression and despair. Conducted in the Open Space Forced Swim Test, a recognized animal model for psychiatric behavior, the study demonstrated significant improvements in depression-like behavior in mice. An oral dose of 30 mg/kg of EB-003 was shown to reduce depression-like symptoms within 30 minutes, with results comparable to the effects of the antidepressant Imipramine. Additionally, extended daily administration of EB-003 over 22 days revealed no adverse effects, indicating the compound's safety for long-term use. These findings support Enveric's plans to proceed with an Investigational New Drug application.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDLc5Zpd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB","EXSR","BK4007","BK4211"],"gpt_icon":0},{"id":"2536227612","title":"Enveric Biosciences files new provisional patent application","url":"https://stock-news.laohu8.com/highlight/detail?id=2536227612","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536227612?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:10","pubTimestamp":1747743017,"startTime":"0","endTime":"0","summary":"Enveric Biosciences (ENVB) announced that it has filed a new provisional patent application with claims to methods and pharmaceutical formulations ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-files-new-provisional-patent-application?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-files-new-provisional-patent-application?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2536061258","title":"Enveric Biosciences Announces New Provisional Patent Application for Promising Neuroplastogen Candidates Targeting Neurodegenerative Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2536061258","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536061258?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:01","pubTimestamp":1747742477,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Announces New Provisional Patent Application for Promising Neuroplastogen Candidates Targeting Neurodegenerative Diseases. Enveric Biosciences Inc., a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, has announced the filing of a new provisional patent application. This application pertains to a newly identified group of molecules with potential to address neurodegenerative diseases. According to Enveric, these molecules might offer therapeutic candidates for conditions such as Alzheimer's Disease by promoting BDNF signaling, a known therapeutic target in neurodegenerative diseases. A prototype molecule from this family has demonstrated promising pharmacokinetic characteristics in preliminary in vivo testing. Further investigation is planned to explore the therapeutic potential of these molecules.Disclaimer: This news brief was created by Public Technologies  using generative a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL3jDY2h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2535988346","title":"BRIEF-Enveric Biosciences Q1 Net Income USD -2.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535988346","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535988346?lang=en_us&edition=fundamental","pubTime":"2025-05-15 05:19","pubTimestamp":1747257563,"startTime":"0","endTime":"0","summary":"BRIEF-Enveric Biosciences Q1 Net Income USD -2.2 MillionMay 14 (Reuters) - Enveric Biosciences Inc ENVB.O:ENVERIC BIOSCIENCES Q1 NET INCOME USD -2.2 MILLIONSource text: ID:nBw7m3FyFaFurther company coverage: ENVB.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nPLX080955:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2535888327","title":"Enveric Biosciences Q1 EPS $(1.22) Up From $(9.21) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535888327","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535888327?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:40","pubTimestamp":1747255236,"startTime":"0","endTime":"0","summary":"Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(1.22) per share. This is a 86.75 percent increase over losses of $(9.21) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45421877/enveric-biosciences-q1-eps-1-22-up-from-9-21-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB"],"gpt_icon":0},{"id":"2535735007","title":"Enveric Biosciences Secures U.S. Patent for Innovative Mescaline Derivative Compounds in EVM401 Series","url":"https://stock-news.laohu8.com/highlight/detail?id=2535735007","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535735007?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:22","pubTimestamp":1747254130,"startTime":"0","endTime":"0","summary":"Enveric Biosciences has announced the issuance of a new U.S. patent for its EVM401 Series, which comprises mescaline derivative compounds aimed at developing neuroplastogenic therapeutics for addiction and neuropsychiatric disorders. This patent broadens Enveric's pipeline and underscores its commitment to advancing treatments for mental health conditions. Preliminary testing of the EVM401 series has shown promising patterns of brain receptor binding and activation, marking a significant step forward in the field of mental health therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire  on May 14, 2025, and is solely responsib","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL5jN9XM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2535700086","title":"Press Release: Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535700086","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535700086?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:15","pubTimestamp":1747253700,"startTime":"0","endTime":"0","summary":"-- Unveiled EVM401 Series with new U.S. Patent for mescaline derivative. Dr. Tucker said: \"Ongoing development of EB-003 is supported by the data accumulated to date, which have demonstrated oral bioavailability and brain exposure in preclinical studies. Preclinical work has also shown encouraging pharmacology and safety results from in vitro pharmacology studies.\". Dr. Tucker concluded: \"As we look ahead to the remainder of 2025 and beyond, we are confident that Enveric is at the leading edge of a paradigm shift in the treatment of severe mental health conditions, an area that has seen minimal innovation for decades. We look forward to bringing our novel technologies to patients in need, while generating value for our shareholders as we capitalize on the substantial potential of the emerging field of neuroplastogenic therapeutics.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4007","BK4555","TM","ENVB","03160","BK4604","BK4099"],"gpt_icon":0},{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGNPF","BK4202","SILO","BETRF","BK4139","KTTA","SNPX","BK4539","FLHLF","MNMD","PBM","RLMD","NRXP","IXHL","ENTBF","ATAI","PHRRF","BK4168","MIRA","SPRC","ENVB","SEEL","BK4547","MYCOF","CYBN","BK4007","ALID","CMPS","PSYGF","NUMIF","DRUG","OPTHF","MDXXF","QNTM","GHRS","RVVTF","CMND"],"gpt_icon":0},{"id":"2523946521","title":"Enveric Biosciences Q4 2024 GAAP EPS $(4.83) Misses $(0.23) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946521","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946521?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:18","pubTimestamp":1743423536,"startTime":"0","endTime":"0","summary":"Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(4.83) per share which missed the analyst consensus estimate of $(0.23) by 2000 percent. This is a 78.1 percent increase over losses of $(22.05) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44559980/enveric-biosciences-q4-2024-gaap-eps-4-83-misses-0-23-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENVB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"ENVB","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.22},{"market":"US","date":"2025-03-28","symbol":"ENVB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-01-29","symbol":"ENVB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-14","symbol":"ENVB","fiscalQuarterEnding":"2024/09","expectedEps":-0.52,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2024-08-12","symbol":"ENVB","fiscalQuarterEnding":"2024/06","expectedEps":-0.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723435200000,"reportTimeType":"post","actualEps":-0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENVB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENVB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741320000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ENVB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ENVB","date":"2025-08-01","current":-0.324133,"percent":0.533333,"low":-320.639018,"twenty":-4.043597,"median":-0.332103,"eighty":-0.167379,"high":-0.058065,"avg":-9.785867,"sd":37.190815,"marketCap":3015420},"quantilePoints":[{"date":"2020-12-31","current":-280.476842,"twenty":-280.476842,"median":-280.476842,"eighty":-280.476842,"marketCap":792872691},{"date":"2021-01-08","current":-298.911939,"twenty":-298.911939,"median":-271.259293,"eighty":-259.408159,"marketCap":844986389},{"date":"2021-01-15","current":-140.596002,"twenty":-298.911939,"median":-259.408159,"eighty":-149.472012,"marketCap":397447182},{"date":"2021-01-22","current":-139.885921,"twenty":-284.163861,"median":-149.827052,"eighty":-143.081285,"marketCap":395439873},{"date":"2021-01-29","current":-131.364951,"twenty":-265.728764,"median":-148.761931,"eighty":-140.453986,"marketCap":371352165},{"date":"2021-02-05","current":-151.602254,"twenty":-259.934876,"median":-149.472012,"eighty":-140.453986,"marketCap":428560471},{"date":"2021-02-12","current":-175.045989,"twenty":-257.30129,"median":-150.892174,"eighty":-141.448099,"marketCap":494832954},{"date":"2021-02-19","current":-160.43665,"twenty":-213.420734,"median":-152.134815,"eighty":-142.300196,"marketCap":468056279},{"date":"2021-02-26","current":-125.559118,"twenty":-179.541263,"median":-151.602254,"eighty":-140.101005,"marketCap":366304914},{"date":"2021-03-05","current":-102.062675,"twenty":-175.516923,"median":-149.649532,"eighty":-134.616645,"marketCap":297756626},{"date":"2021-03-12","current":-135.838811,"twenty":-174.400276,"median":-148.05185,"eighty":-132.754903,"marketCap":396294790},{"date":"2021-03-19","current":-136.138295,"twenty":-173.119122,"median":-143.613845,"eighty":-132.754903,"marketCap":397168501},{"date":"2021-03-26","current":-116.477996,"twenty":-169.027537,"median":-141.661123,"eighty":-131.048595,"marketCap":339811742},{"date":"2021-04-01","current":-8.8686,"twenty":-166.237335,"median":-140.244394,"eighty":-126.440234,"marketCap":60880065},{"date":"2021-04-09","current":-7.905238,"twenty":-163.520558,"median":-138.8208,"eighty":-117.173389,"marketCap":54266895},{"date":"2021-04-16","current":-6.743536,"twenty":-159.459183,"median":-137.674471,"eighty":-107.720259,"marketCap":46292190},{"date":"2021-04-23","current":-6.630199,"twenty":-155.86274,"median":-135.909644,"eighty":-43.943438,"marketCap":45514170},{"date":"2021-04-30","current":-6.743536,"twenty":-152.52536,"median":-133.63602,"eighty":-8.20558,"marketCap":46292190},{"date":"2021-05-07","current":-6.488528,"twenty":-152.170319,"median":-132.167492,"eighty":-7.344221,"marketCap":44541645},{"date":"2021-05-14","current":-5.411829,"twenty":-151.824571,"median":-131.364951,"eighty":-6.941875,"marketCap":37150455},{"date":"2021-05-21","current":-6.452474,"twenty":-151.616192,"median":-128.055137,"eighty":-6.726536,"marketCap":58181480},{"date":"2021-05-28","current":-5.29008,"twenty":-151.03419,"median":-123.896977,"eighty":-6.596198,"marketCap":47700257},{"date":"2021-06-04","current":-5.59847,"twenty":-150.111085,"median":-118.216479,"eighty":-6.465861,"marketCap":50480990},{"date":"2021-06-11","current":-5.645915,"twenty":-149.756044,"median":-112.026608,"eighty":-6.142851,"marketCap":50908795},{"date":"2021-06-18","current":-5.100301,"twenty":-149.18798,"median":-107.569653,"eighty":-5.892627,"marketCap":45989037},{"date":"2021-06-25","current":-5.147746,"twenty":-147.625802,"median":-99.309185,"eighty":-5.745548,"marketCap":46416842},{"date":"2021-07-02","current":-5.205428,"twenty":-145.495559,"median":-8.500256,"eighty":-5.660148,"marketCap":46936956},{"date":"2021-07-09","current":-5.538195,"twenty":-143.791365,"median":-8.273582,"eighty":-5.645915,"marketCap":49937492},{"date":"2021-07-16","current":-4.706277,"twenty":-143.436325,"median":-7.777734,"eighty":-5.456136,"marketCap":42436152},{"date":"2021-07-23","current":-4.563663,"twenty":-142.726244,"median":-7.31022,"eighty":-5.408691,"marketCap":41150208},{"date":"2021-07-30","current":-4.539894,"twenty":-141.661123,"median":-7.026878,"eighty":-5.313802,"marketCap":40935884},{"date":"2021-08-06","current":-4.563663,"twenty":-140.596002,"median":-6.885207,"eighty":-5.266357,"marketCap":41150208},{"date":"2021-08-13","current":-4.047924,"twenty":-140.244394,"median":-6.729369,"eighty":-5.171468,"marketCap":36863728},{"date":"2021-08-20","current":-3.953786,"twenty":-140.244394,"median":-6.630199,"eighty":-5.062813,"marketCap":36006432},{"date":"2021-08-27","current":-4.259734,"twenty":-139.885921,"median":-6.531029,"eighty":-4.910522,"marketCap":38792644},{"date":"2021-09-03","current":-6.189558,"twenty":-137.755679,"median":-6.460194,"eighty":-4.89643,"marketCap":56367212},{"date":"2021-09-10","current":-8.119382,"twenty":-137.690713,"median":-6.488528,"eighty":-4.907704,"marketCap":73941780},{"date":"2021-09-17","current":-8.615408,"twenty":-137.674471,"median":-6.531029,"eighty":-4.93589,"marketCap":78459000},{"date":"2021-09-24","current":-7.719405,"twenty":-136.44553,"median":-6.630199,"eighty":-4.943621,"marketCap":70299264},{"date":"2021-10-01","current":-7.099096,"twenty":-136.01204,"median":-6.675957,"eighty":-4.993123,"marketCap":64650216},{"date":"2021-10-08","current":-6.651095,"twenty":-135.867144,"median":-6.630199,"eighty":-5.02439,"marketCap":60570348},{"date":"2021-10-15","current":-6.513248,"twenty":-135.384078,"median":-6.633456,"eighty":-5.056077,"marketCap":59315004},{"date":"2021-10-22","current":-6.099709,"twenty":-133.962895,"median":-6.630199,"eighty":-5.092803,"marketCap":55548972},{"date":"2021-10-29","current":-6.065247,"twenty":-133.048609,"median":-6.595082,"eighty":-5.138257,"marketCap":55235136},{"date":"2021-11-05","current":-7.168019,"twenty":-132.60805,"median":-6.616633,"eighty":-5.155861,"marketCap":65277888},{"date":"2021-11-12","current":-6.168632,"twenty":-131.947213,"median":-6.595082,"eighty":-5.168752,"marketCap":56176644},{"date":"2021-11-19","current":-4.517674,"twenty":-131.506654,"median":-6.513248,"eighty":-5.056077,"marketCap":50841432},{"date":"2021-11-26","current":-4.043597,"twenty":-131.392262,"median":-6.513248,"eighty":-4.988793,"marketCap":45506220},{"date":"2021-12-03","current":-3.206991,"twenty":-130.890416,"median":-6.474361,"eighty":-4.904885,"marketCap":36091140},{"date":"2021-12-10","current":-3.346425,"twenty":-129.238643,"median":-6.444325,"eighty":-4.774013,"marketCap":37660320},{"date":"2021-12-17","current":-3.290652,"twenty":-127.996491,"median":-6.388385,"eighty":-4.697107,"marketCap":37032648},{"date":"2021-12-23","current":-2.983896,"twenty":-126.880793,"median":-6.32554,"eighty":-4.644478,"marketCap":33580452},{"date":"2021-12-31","current":-2.59348,"twenty":-124.894262,"median":-6.306478,"eighty":-4.563663,"marketCap":29186748},{"date":"2022-01-07","current":-2.34194,"twenty":-122.70994,"median":-6.254322,"eighty":-4.549402,"marketCap":26355947},{"date":"2022-01-14","current":-2.088169,"twenty":-119.844223,"median":-6.189558,"eighty":-4.526562,"marketCap":23500039},{"date":"2022-01-21","current":-1.761335,"twenty":-117.868782,"median":-6.167806,"eighty":-4.473884,"marketCap":19821881},{"date":"2022-01-28","current":-1.672934,"twenty":-115.958667,"median":-6.099709,"eighty":-4.269148,"marketCap":18827021},{"date":"2022-02-04","current":-1.728986,"twenty":-113.139455,"median":-6.063516,"eighty":-4.160722,"marketCap":19457832},{"date":"2022-02-11","current":-0.97441,"twenty":-109.726724,"median":-5.946223,"eighty":-4.044462,"marketCap":10965906},{"date":"2022-02-18","current":-1.307232,"twenty":-107.870866,"median":-5.883138,"eighty":-3.800914,"marketCap":14711450},{"date":"2022-02-25","current":-1.31751,"twenty":-107.569653,"median":-5.811971,"eighty":-3.513747,"marketCap":14827122},{"date":"2022-03-04","current":-1.205382,"twenty":-107.569653,"median":-5.752665,"eighty":-3.318539,"marketCap":13565240},{"date":"2022-03-11","current":-1.298822,"twenty":-102.062675,"median":-5.686169,"eighty":-3.206991,"marketCap":14616809},{"date":"2022-03-18","current":-1.277798,"twenty":-96.555696,"median":-5.645915,"eighty":-3.067557,"marketCap":14380206},{"date":"2022-03-25","current":-1.710427,"twenty":-8.8686,"median":-5.59847,"eighty":-2.900235,"marketCap":19248970},{"date":"2022-04-01","current":-0.335415,"twenty":-8.753254,"median":-5.473396,"eighty":-2.691084,"marketCap":16427585},{"date":"2022-04-08","current":-0.311257,"twenty":-8.615408,"median":-5.443118,"eighty":-2.412494,"marketCap":15244420},{"date":"2022-04-14","current":-0.322424,"twenty":-8.523286,"median":-5.408691,"eighty":-2.281147,"marketCap":15791305},{"date":"2022-04-22","current":-0.299018,"twenty":-8.454921,"median":-5.348648,"eighty":-1.926394,"marketCap":14644950},{"date":"2022-04-29","current":-0.289999,"twenty":-8.307583,"median":-5.29008,"eighty":-1.849012,"marketCap":14203235},{"date":"2022-05-06","current":-0.243079,"twenty":-8.24436,"median":-5.271546,"eighty":-1.800544,"marketCap":11905266},{"date":"2022-05-13","current":-0.209689,"twenty":-8.175607,"median":-5.205428,"eighty":-1.74622,"marketCap":10536900},{"date":"2022-05-20","current":-0.222689,"twenty":-8.127555,"median":-5.183329,"eighty":-1.725052,"marketCap":11190187},{"date":"2022-05-27","current":-0.215875,"twenty":-8.047524,"median":-5.147746,"eighty":-1.672265,"marketCap":10847738},{"date":"2022-06-03","current":-0.223528,"twenty":-7.988206,"median":-5.062813,"eighty":-1.556624,"marketCap":11232335},{"date":"2022-06-10","current":-0.230658,"twenty":-7.927398,"median":-5.012525,"eighty":-1.435245,"marketCap":11590590},{"date":"2022-06-17","current":-0.195325,"twenty":-7.876446,"median":-4.943968,"eighty":-1.350027,"marketCap":9815122},{"date":"2022-06-24","current":-0.190817,"twenty":-7.802113,"median":-4.910522,"eighty":-1.322369,"marketCap":9588579},{"date":"2022-07-01","current":-0.222899,"twenty":-7.691735,"median":-4.844076,"eighty":-1.294057,"marketCap":11200724},{"date":"2022-07-08","current":-0.253304,"twenty":-7.629603,"median":-4.77312,"eighty":-1.254625,"marketCap":12728575},{"date":"2022-07-15","current":-0.166912,"twenty":-7.516722,"median":-4.706277,"eighty":-1.216688,"marketCap":8387372},{"date":"2022-07-22","current":-0.202559,"twenty":-7.384727,"median":-4.682931,"eighty":-0.964683,"marketCap":10178645},{"date":"2022-07-29","current":-0.149083,"twenty":-7.33624,"median":-4.63497,"eighty":-0.340611,"marketCap":7491475},{"date":"2022-08-05","current":-0.224524,"twenty":-7.302457,"median":-4.564672,"eighty":-0.322252,"marketCap":11282352},{"date":"2022-08-12","current":-0.202085,"twenty":-7.264512,"median":-4.563663,"eighty":-0.311365,"marketCap":10535171},{"date":"2022-08-19","current":-0.204803,"twenty":-7.223157,"median":-4.551779,"eighty":-0.300589,"marketCap":10676899},{"date":"2022-08-26","current":-0.188492,"twenty":-7.165309,"median":-4.539894,"eighty":-0.289913,"marketCap":9826527},{"date":"2022-09-02","current":-0.167649,"twenty":-7.150287,"median":-4.517674,"eighty":-0.271682,"marketCap":8739940},{"date":"2022-09-09","current":-0.163722,"twenty":-7.133557,"median":-4.481832,"eighty":-0.254675,"marketCap":8535220},{"date":"2022-09-16","current":-0.177315,"twenty":-7.099096,"median":-4.397279,"eighty":-0.239045,"marketCap":9243864},{"date":"2022-09-23","current":-0.180988,"twenty":-7.083546,"median":-4.236199,"eighty":-0.230448,"marketCap":9435350},{"date":"2022-09-30","current":-0.168231,"twenty":-7.030173,"median":-4.183032,"eighty":-0.228141,"marketCap":8770303},{"date":"2022-10-07","current":-0.159062,"twenty":-7.026878,"median":-4.148603,"eighty":-0.224681,"marketCap":8292301},{"date":"2022-10-14","current":-0.136339,"twenty":-7.026878,"median":-4.043597,"eighty":-0.222899,"marketCap":7107686},{"date":"2022-10-21","current":-0.149893,"twenty":-6.989729,"median":-3.865786,"eighty":-0.220173,"marketCap":7814298},{"date":"2022-10-28","current":-0.137535,"twenty":-6.885207,"median":-3.625294,"eighty":-0.217815,"marketCap":7170034},{"date":"2022-11-04","current":-0.122386,"twenty":-6.885207,"median":-3.499804,"eighty":-0.214826,"marketCap":6380291},{"date":"2022-11-11","current":-0.133947,"twenty":-6.823403,"median":-3.346425,"eighty":-0.209794,"marketCap":6982990},{"date":"2022-11-18","current":-0.118932,"twenty":-6.823403,"median":-3.290652,"eighty":-0.209335,"marketCap":6172464},{"date":"2022-11-25","current":-0.123738,"twenty":-6.759509,"median":-3.248822,"eighty":-0.207205,"marketCap":6421857},{"date":"2022-12-02","current":-0.124138,"twenty":-6.743536,"median":-3.151217,"eighty":-0.203146,"marketCap":6442640},{"date":"2022-12-09","current":-0.104917,"twenty":-6.720869,"median":-3.025727,"eighty":-0.201787,"marketCap":5445070},{"date":"2022-12-16","current":-0.082091,"twenty":-6.691485,"median":-2.956009,"eighty":-0.196867,"marketCap":4260455},{"date":"2022-12-23","current":-0.070478,"twenty":-6.657987,"median":-2.872348,"eighty":-0.191082,"marketCap":3657756},{"date":"2022-12-30","current":-0.083293,"twenty":-6.651095,"median":-2.75383,"eighty":-0.189087,"marketCap":4322803},{"date":"2023-01-06","current":-0.109722,"twenty":-6.651095,"median":-2.596408,"eighty":-0.188295,"marketCap":5694462},{"date":"2023-01-13","current":-0.113326,"twenty":-6.651095,"median":-2.412494,"eighty":-0.183494,"marketCap":5881506},{"date":"2023-01-20","current":-0.112525,"twenty":-6.648218,"median":-2.314611,"eighty":-0.177375,"marketCap":5839941},{"date":"2023-01-27","current":-0.114528,"twenty":-6.635409,"median":-2.174061,"eighty":-0.173271,"marketCap":5943855},{"date":"2023-02-03","current":-0.115328,"twenty":-6.630199,"median":-1.930051,"eighty":-0.170174,"marketCap":5985420},{"date":"2023-02-10","current":-0.105718,"twenty":-6.630199,"median":-1.867724,"eighty":-0.168007,"marketCap":5486635},{"date":"2023-02-17","current":-0.100111,"twenty":-6.627486,"median":-1.840534,"eighty":-0.165234,"marketCap":5195677},{"date":"2023-02-24","current":-0.086656,"twenty":-6.616633,"median":-1.809474,"eighty":-0.163118,"marketCap":4497378},{"date":"2023-03-03","current":-0.077686,"twenty":-6.616633,"median":-1.767889,"eighty":-0.157267,"marketCap":4031845},{"date":"2023-03-10","current":-0.071279,"twenty":-6.573531,"median":-1.748228,"eighty":-0.149525,"marketCap":3699322},{"date":"2023-03-17","current":-0.072481,"twenty":-6.513248,"median":-1.728986,"eighty":-0.148152,"marketCap":3761670},{"date":"2023-03-24","current":-0.065273,"twenty":-6.513248,"median":-1.710427,"eighty":-0.147103,"marketCap":3387581},{"date":"2023-03-31","current":-0.066642,"twenty":-6.513248,"median":-1.677431,"eighty":-0.143493,"marketCap":3458658},{"date":"2023-04-06","current":-0.058065,"twenty":-6.513248,"median":-1.669217,"eighty":-0.140804,"marketCap":3013492},{"date":"2023-04-14","current":-0.153018,"twenty":-6.493472,"median":-1.471687,"eighty":-0.141803,"marketCap":2826448},{"date":"2023-04-21","current":-0.184522,"twenty":-6.488528,"median":-1.451598,"eighty":-0.142443,"marketCap":3408364},{"date":"2023-04-28","current":-0.199644,"twenty":-6.465861,"median":-1.415623,"eighty":-0.143307,"marketCap":3687684},{"date":"2023-05-05","current":-0.216026,"twenty":-6.454018,"median":-1.348812,"eighty":-0.144467,"marketCap":3990280},{"date":"2023-05-12","current":-0.187852,"twenty":-6.445955,"median":-1.329658,"eighty":-0.145026,"marketCap":3469881},{"date":"2023-05-19","current":-0.400593,"twenty":-6.444325,"median":-1.303495,"eighty":-0.145108,"marketCap":7460992},{"date":"2023-05-26","current":-0.431838,"twenty":-6.409959,"median":-1.29088,"eighty":-0.146704,"marketCap":8042908},{"date":"2023-06-02","current":-0.495442,"twenty":-6.385788,"median":-1.277798,"eighty":-0.147313,"marketCap":9227523},{"date":"2023-06-09","current":-0.454155,"twenty":-6.354725,"median":-1.236918,"eighty":-0.147482,"marketCap":8458562},{"date":"2023-06-16","current":-0.430722,"twenty":-6.32246,"median":-1.214726,"eighty":-0.14774,"marketCap":8022126},{"date":"2023-06-23","current":-0.422911,"twenty":-6.308675,"median":-1.16894,"eighty":-0.148001,"marketCap":7876647},{"date":"2023-06-30","current":-0.359307,"twenty":-6.306478,"median":-0.962251,"eighty":-0.148261,"marketCap":6692032},{"date":"2023-07-07","current":-0.324715,"twenty":-6.306478,"median":-0.516643,"eighty":-0.148697,"marketCap":6047768},{"date":"2023-07-14","current":-0.321367,"twenty":-6.306478,"median":-0.47703,"eighty":-0.149083,"marketCap":5985420},{"date":"2023-07-21","current":-0.320252,"twenty":-6.272017,"median":-0.459734,"eighty":-0.149096,"marketCap":5964637},{"date":"2023-07-28","current":-0.282312,"twenty":-6.236627,"median":-0.457502,"eighty":-0.149525,"marketCap":5258025},{"date":"2023-08-04","current":-0.281197,"twenty":-6.233521,"median":-0.440764,"eighty":-0.149643,"marketCap":5237242},{"date":"2023-08-11","current":-0.313556,"twenty":-6.189558,"median":-0.43128,"eighty":-0.149643,"marketCap":5839941},{"date":"2023-08-18","current":-0.212948,"twenty":-6.168632,"median":-0.422911,"eighty":-0.149893,"marketCap":4725393},{"date":"2023-08-25","current":-0.21198,"twenty":-6.167806,"median":-0.412868,"eighty":-0.150292,"marketCap":4703914},{"date":"2023-09-01","current":-0.209076,"twenty":-6.120184,"median":-0.400593,"eighty":-0.15118,"marketCap":4639476},{"date":"2023-09-08","current":-0.217302,"twenty":-6.103804,"median":-0.395014,"eighty":-0.151678,"marketCap":4822025},{"date":"2023-09-15","current":-0.211403,"twenty":-6.099709,"median":-0.36656,"eighty":-0.152775,"marketCap":4691110},{"date":"2023-09-22","current":-0.234028,"twenty":-6.072139,"median":-0.354312,"eighty":-0.153018,"marketCap":5193168},{"date":"2023-09-29","current":-0.234018,"twenty":-6.063862,"median":-0.348857,"eighty":-0.156417,"marketCap":5192950},{"date":"2023-10-06","current":-0.232051,"twenty":-5.995125,"median":-0.34336,"eighty":-0.157598,"marketCap":5149312},{"date":"2023-10-12","current":-0.202553,"twenty":-5.968328,"median":-0.339924,"eighty":-0.15851,"marketCap":4494738},{"date":"2023-10-20","current":-0.19862,"twenty":-5.943095,"median":-0.331533,"eighty":-0.159633,"marketCap":4407462},{"date":"2023-10-27","current":-0.17748,"twenty":-5.930583,"median":-0.330852,"eighty":-0.160014,"marketCap":3938351},{"date":"2023-11-03","current":-0.184854,"twenty":-5.9274,"median":-0.324715,"eighty":-0.1618,"marketCap":4101994},{"date":"2023-11-10","current":-0.183066,"twenty":-5.883138,"median":-0.323041,"eighty":-0.16188,"marketCap":4062301},{"date":"2023-11-17","current":-0.148342,"twenty":-5.836842,"median":-0.322209,"eighty":-0.159062,"marketCap":3342693},{"date":"2023-11-24","current":-0.145252,"twenty":-5.816945,"median":-0.321367,"eighty":-0.156171,"marketCap":3273054},{"date":"2023-12-01","current":-0.152463,"twenty":-5.786533,"median":-0.319083,"eighty":-0.153018,"marketCap":3435546},{"date":"2023-12-08","current":-0.154574,"twenty":-5.767656,"median":-0.313556,"eighty":-0.153398,"marketCap":3483133},{"date":"2023-12-15","current":-0.151432,"twenty":-5.745548,"median":-0.311311,"eighty":-0.152907,"marketCap":3412333},{"date":"2023-12-22","current":-0.13701,"twenty":-5.721826,"median":-0.309093,"eighty":-0.151382,"marketCap":3087348},{"date":"2023-12-29","current":-0.160704,"twenty":-5.704717,"median":-0.307079,"eighty":-0.150713,"marketCap":3621251},{"date":"2024-01-05","current":-0.13289,"twenty":-5.686169,"median":-0.30463,"eighty":-0.149893,"marketCap":2994496},{"date":"2024-01-12","current":-0.154996,"twenty":-5.645915,"median":-0.299233,"eighty":-0.149525,"marketCap":3492626},{"date":"2024-01-19","current":-0.130075,"twenty":-5.645915,"median":-0.294587,"eighty":-0.149317,"marketCap":2931067},{"date":"2024-01-26","current":-0.107281,"twenty":-5.645915,"median":-0.291072,"eighty":-0.148304,"marketCap":2417445},{"date":"2024-02-02","current":-0.109822,"twenty":-5.645915,"median":-0.287529,"eighty":-0.147383,"marketCap":2474697},{"date":"2024-02-09","current":-0.098674,"twenty":-5.607959,"median":-0.282312,"eighty":-0.145223,"marketCap":2223501},{"date":"2024-02-16","current":-0.102103,"twenty":-5.55025,"median":-0.279155,"eighty":-0.144221,"marketCap":2300750},{"date":"2024-02-23","current":-0.10333,"twenty":-5.509672,"median":-0.276176,"eighty":-0.14312,"marketCap":2328417},{"date":"2024-03-01","current":-0.17627,"twenty":-5.469944,"median":-0.269814,"eighty":-0.1414,"marketCap":3972006},{"date":"2024-03-08","current":-0.184779,"twenty":-5.456136,"median":-0.264382,"eighty":-0.141817,"marketCap":4163758},{"date":"2024-03-15","current":-0.263474,"twenty":-5.448325,"median":-0.265483,"eighty":-0.142326,"marketCap":5937046},{"date":"2024-03-22","current":-0.280241,"twenty":-5.424345,"median":-0.266038,"eighty":-0.14312,"marketCap":6314858},{"date":"2024-03-28","current":-0.430257,"twenty":-5.410574,"median":-0.270237,"eighty":-0.143784,"marketCap":7439885},{"date":"2024-04-05","current":-0.401151,"twenty":-5.408691,"median":-0.273386,"eighty":-0.144221,"marketCap":6936598},{"date":"2024-04-12","current":-0.383983,"twenty":-5.398613,"median":-0.27906,"eighty":-0.144221,"marketCap":6639732},{"date":"2024-04-19","current":-0.395667,"twenty":-5.355618,"median":-0.280241,"eighty":-0.144417,"marketCap":6841776},{"date":"2024-04-26","current":-0.379638,"twenty":-5.313802,"median":-0.281755,"eighty":-0.144869,"marketCap":6564604},{"date":"2024-05-03","current":-0.390395,"twenty":-5.304313,"median":-0.285031,"eighty":-0.145107,"marketCap":6750601},{"date":"2024-05-10","current":-0.388075,"twenty":-5.29008,"median":-0.288659,"eighty":-0.145166,"marketCap":6710484},{"date":"2024-05-17","current":-0.435575,"twenty":-5.284742,"median":-0.291072,"eighty":-0.145252,"marketCap":6564604},{"date":"2024-05-24","current":-0.395212,"twenty":-5.272584,"median":-0.294587,"eighty":-0.14587,"marketCap":5956284},{"date":"2024-05-31","current":-0.36206,"twenty":-5.261613,"median":-0.299233,"eighty":-0.146858,"marketCap":5456645},{"date":"2024-06-07","current":-0.370239,"twenty":-5.235194,"median":-0.30463,"eighty":-0.147173,"marketCap":5579913},{"date":"2024-06-14","current":-0.385771,"twenty":-5.205428,"median":-0.309003,"eighty":-0.147453,"marketCap":5814003},{"date":"2024-06-21","current":-0.324665,"twenty":-5.201974,"median":-0.310209,"eighty":-0.147491,"marketCap":4893065},{"date":"2024-06-28","current":-0.323842,"twenty":-5.199927,"median":-0.311257,"eighty":-0.147581,"marketCap":4880662},{"date":"2024-07-05","current":-0.266233,"twenty":-5.19519,"median":-0.310209,"eighty":-0.1479,"marketCap":4012437},{"date":"2024-07-12","current":-0.260576,"twenty":-5.171468,"median":-0.307079,"eighty":-0.148152,"marketCap":3927165},{"date":"2024-07-15","current":-0.265513,"twenty":-5.168752,"median":-0.305155,"eighty":-0.14819,"marketCap":4001584},{"date":"2024-08-02","current":-0.276639,"twenty":-5.166037,"median":-0.304893,"eighty":-0.148228,"marketCap":4169257},{"date":"2024-08-09","current":-0.292409,"twenty":-5.153832,"median":-0.303514,"eighty":-0.148484,"marketCap":4406936},{"date":"2024-08-16","current":-0.406658,"twenty":-5.128768,"median":-0.304072,"eighty":-0.148851,"marketCap":4308321},{"date":"2024-08-23","current":-0.447239,"twenty":-5.085306,"median":-0.306765,"eighty":-0.149088,"marketCap":4738261},{"date":"2024-08-30","current":-0.421897,"twenty":-5.049341,"median":-0.309651,"eighty":-0.149206,"marketCap":4469771},{"date":"2024-09-06","current":-0.443703,"twenty":-5.027235,"median":-0.311311,"eighty":-0.149403,"marketCap":4700797},{"date":"2024-09-13","current":-0.421055,"twenty":-5.016793,"median":-0.313556,"eighty":-0.149525,"marketCap":4460851},{"date":"2024-09-20","current":-0.413393,"twenty":-4.997102,"median":-0.317041,"eighty":-0.149549,"marketCap":4379680},{"date":"2024-09-27","current":-0.403795,"twenty":-4.959885,"median":-0.320252,"eighty":-0.149643,"marketCap":4277993},{"date":"2024-10-04","current":-0.354626,"twenty":-4.943621,"median":-0.322097,"eighty":-0.149693,"marketCap":3757070},{"date":"2024-10-11","current":-0.367508,"twenty":-4.93589,"median":-0.322424,"eighty":-0.149973,"marketCap":3893545},{"date":"2024-10-18","current":-0.370875,"twenty":-4.907704,"median":-0.323721,"eighty":-0.150314,"marketCap":3929224},{"date":"2024-10-25","current":-0.448081,"twenty":-4.894504,"median":-0.324715,"eighty":-0.150558,"marketCap":4747181},{"date":"2024-10-31","current":-0.422823,"twenty":-4.8868,"median":-0.325831,"eighty":-0.15118,"marketCap":4479583},{"date":"2024-11-08","current":-0.399922,"twenty":-4.801353,"median":-0.330577,"eighty":-0.151432,"marketCap":4236962},{"date":"2024-11-15","current":-0.334251,"twenty":-4.777584,"median":-0.331657,"eighty":-0.151432,"marketCap":3541208},{"date":"2024-11-22","current":-0.304894,"twenty":-4.768656,"median":-0.330593,"eighty":-0.151803,"marketCap":3005121},{"date":"2024-11-29","current":-0.333069,"twenty":-4.737768,"median":-0.330309,"eighty":-0.152331,"marketCap":3282818},{"date":"2024-12-06","current":-0.338719,"twenty":-4.711031,"median":-0.330647,"eighty":-0.152907,"marketCap":3338509},{"date":"2024-12-13","current":-0.358546,"twenty":-4.706277,"median":-0.331136,"eighty":-0.153018,"marketCap":3533927},{"date":"2024-12-20","current":-0.331353,"twenty":-4.687938,"median":-0.33141,"eighty":-0.153398,"marketCap":3265911},{"date":"2024-12-27","current":-0.312788,"twenty":-4.682846,"median":-0.330861,"eighty":-0.154111,"marketCap":3082925},{"date":"2025-01-03","current":-0.393507,"twenty":-4.673,"median":-0.331353,"eighty":-0.154523,"marketCap":3878518},{"date":"2025-01-10","current":-0.41964,"twenty":-4.653985,"median":-0.331657,"eighty":-0.154523,"marketCap":4136092},{"date":"2025-01-17","current":-0.353249,"twenty":-4.625819,"median":-0.333069,"eighty":-0.154523,"marketCap":3481716},{"date":"2025-01-24","current":-0.335995,"twenty":-4.589216,"median":-0.334114,"eighty":-0.154523,"marketCap":3311658},{"date":"2025-01-31","current":-0.268273,"twenty":-4.565681,"median":-0.333069,"eighty":-0.154574,"marketCap":2644176},{"date":"2025-02-07","current":-0.325103,"twenty":-4.563663,"median":-0.331533,"eighty":-0.154523,"marketCap":3204304},{"date":"2025-02-14","current":-0.307687,"twenty":-4.563663,"median":-0.330861,"eighty":-0.154523,"marketCap":3032645},{"date":"2025-02-21","current":-0.265114,"twenty":-4.563663,"median":-0.330325,"eighty":-0.154523,"marketCap":2613033},{"date":"2025-02-28","current":-0.410249,"twenty":-4.563663,"median":-0.330309,"eighty":-0.154564,"marketCap":4043526},{"date":"2025-03-07","current":-0.371546,"twenty":-4.563663,"median":-0.330861,"eighty":-0.154912,"marketCap":3662062},{"date":"2025-03-14","current":-0.317362,"twenty":-4.544648,"median":-0.330754,"eighty":-0.155482,"marketCap":3128011},{"date":"2025-03-21","current":-0.334779,"twenty":-4.539894,"median":-0.331353,"eighty":-0.156387,"marketCap":3299670},{"date":"2025-03-28","current":-0.309622,"twenty":-4.539894,"median":-0.331107,"eighty":-0.156583,"marketCap":3051718},{"date":"2025-04-04","current":-0.330415,"twenty":-4.539894,"median":-0.330647,"eighty":-0.15713,"marketCap":3163719},{"date":"2025-04-11","current":-0.30202,"twenty":-4.522118,"median":-0.330309,"eighty":-0.157598,"marketCap":2891837},{"date":"2025-04-17","current":-0.317508,"twenty":-4.517674,"median":-0.329688,"eighty":-0.15851,"marketCap":3040136},{"date":"2025-04-25","current":-0.344561,"twenty":-4.504116,"median":-0.329335,"eighty":-0.159429,"marketCap":3299166},{"date":"2025-05-02","current":-0.330415,"twenty":-4.479183,"median":-0.330309,"eighty":-0.159878,"marketCap":3163719},{"date":"2025-05-09","current":-0.327834,"twenty":-4.440063,"median":-0.330294,"eighty":-0.160428,"marketCap":3139003},{"date":"2025-05-16","current":-0.33476,"twenty":-4.406787,"median":-0.330415,"eighty":-0.161322,"marketCap":3114286},{"date":"2025-05-23","current":-0.321476,"twenty":-4.342993,"median":-0.330415,"eighty":-0.161774,"marketCap":2990703},{"date":"2025-05-30","current":-0.321476,"twenty":-4.287975,"median":-0.330415,"eighty":-0.161832,"marketCap":2990703},{"date":"2025-06-06","current":-0.33476,"twenty":-4.240906,"median":-0.330415,"eighty":-0.162375,"marketCap":3114286},{"date":"2025-06-13","current":-0.329446,"twenty":-4.203251,"median":-0.330415,"eighty":-0.16336,"marketCap":3064853},{"date":"2025-06-20","current":-0.33476,"twenty":-4.18791,"median":-0.330647,"eighty":-0.163773,"marketCap":3114286},{"date":"2025-06-27","current":-0.337417,"twenty":-4.177455,"median":-0.331107,"eighty":-0.164145,"marketCap":3139003},{"date":"2025-07-03","current":-0.33476,"twenty":-4.155145,"median":-0.330754,"eighty":-0.164815,"marketCap":3114286},{"date":"2025-07-11","current":-0.358672,"twenty":-4.155145,"median":-0.33141,"eighty":-0.165282,"marketCap":3336735},{"date":"2025-07-18","current":-0.340074,"twenty":-4.142061,"median":-0.33188,"eighty":-0.166912,"marketCap":3163719},{"date":"2025-07-25","current":-0.350701,"twenty":-4.047924,"median":-0.332103,"eighty":-0.167045,"marketCap":3262585},{"date":"2025-08-01","current":-0.324133,"twenty":-4.043597,"median":-0.332103,"eighty":-0.167379,"marketCap":3015420}],"updateTime":1754139314457}}}